Partner Content Partner Content Peripheral Interventions Market will achieve 8.7% CAGR up to... Peripheral Intervention Industry to hit $10.5bn by 2025
News Disappointment for BMS as Zeposia fails Crohn’s study Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.
Digital Sponsored Innovation as Strategy: Enabling life sciences of the future Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.